DAFTAR PUSTAKA

1. University of Rochester Medical Center. Top 10 Most Common Health

Issues. New York: The University; 2013;4–7.
2. World Health Organization (2018). HIV/AIDS Data and Statistics 2018.
Available from: http://www.who.int/hiv/data/2017_summary-global-hiv-
epidemic.png – Diakses Oktober 2018.
3. Asfiah N. Pencegahan Penyebaran HIV/AIDS Melalui Penguatan Budaya.
HUMANITY. 2011;6:116–20.
4. Joint United Nations Programme on HIV/AIDS (2018) . UNAIDS DATA
2018. Available from:
http://www.unaids.org/sites/default/files/media_asset/unaids-data-
2018_en.pdf – Diakses Oktober 2018.
5. Yuni H. Analisis Faktor Faktor yang Berhubungan dengan Kepatuhan ARV
di Poliklinik VCT RSUP Dr. M. Djamil Padang. J Kesehat Andalas. 2017;6
6. Diatmi K, Diah IG. Hubungan Antara Dukungan Sosial dengan Kualitas
Hidup pada Orang Dengan HIV dan AIDS ( ODHA ) Di Yayasan Spirit
Paramacitta. J Psikol Udayana. 2014;1(2):353–62.
7. University of Bristol. Survival of HIV- Positive Patients Starting
Antiretroviral Therapy Between 1996 and 2013: Collaborative Analysis Of
Cohort Studies. Bristol: The University; 2017;349–56.
8. Sumantri R. Kegagalan Terapi Infeksi HIV / AIDS dan Resistensi
Antiretroviral. Glob Med Heal Commun. 2013;1(1):31–3.
9. Yuliandra Y, Nosa US, Raveinal R, Almasdy D. Terapi Antiretroviral pada
Pasien HIV/AIDS di RSUP. Dr. M. Djamil Padang: Kajian
Sosiodemografidan Evaluasi Obat. J Sains Farm Klin. 2017 Dec 15;4(1):1.
10. Clavel, Francois J, Allan M H. Medical Progress: HIV Drug Resistance. N
Engl J Med. 2004;350(10):1023–35.
11. Muktiarti D, Munasir Z, Kurniati N. Terapi Antiretroviral Lini Kedua pada
HIV Anak di RS. Cipto Mangunkusumo. Sari Pediatr. 2012;14(2).
12. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan
 Republik Indonesia Nomor 87 Tahun 2014. Kementrian; 2015.
13. Nurtakyidah. Studi Penggunaan Obat di Unit Perawatan Intensif Umum
Rumah Sakit DR. Hasan Sadikin Bandung. J Iqra. 2013;7(2):41–52.
14. WHO (2015). Report A. Essential Medicines and Health Products The
Pursuit of Responsible Use of Medicines : Sharing and Learning from
Country Experiences. Available from:
http://www.who.int/medicines/areas/rational_use/en/ Diakses Oktober
2018.
15. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA, editors. Jawetz,
Melnick and Aldelberg’s Medical Microbiology. New York: McGraw-Hill
Companies;2013..
16. Alwi I, Sudoyo AW. Buku Ajar Ilmu Penyakit Dalam. In: Djoerban Z,
Djauzi S, editors. Infeksi HIV dan AIDS. Jakarta: Interna Publishing; 2014.
p. 887 - 924
17. Pagadala M. HIV-AIDS. Allg Homöopathische Zeitung. 2017;262(02):2–
76.
18. Nsuami MU, Witbooi PJ. A Model of HIV/AIDS Population Dynamics
Including ARV Treatment And Pre-Exposure Prophylaxis. Adv Differ
Equations. 2018;2018(1):1–12.
19. Ministry of Health of the Republic Indonesia. Kajian Epidemiologi HIV
Indonesia 2016. Jakarta: The Ministry; 2017.
20. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang. Padang :
Instansi; 2018.
21. Dias MVS, Costa CS, DaSilva LLP. The Ambiguous Roles of Extracellular
Vesicles in HIV Replication and Pathogenesis. Frontiers in Microbiology.
2018;9:1–13.
22. Adojaan M, Kivisild T, Mannik A, Krispin T, Ustina V, Zilmer K, et al.
Predominance of A Rare Type Of HIV-1 In Estonia. JAIDS, J Acquir
Immune Defic Syndr. 2005;39(5):598–605.
23. Center for Disease Control and Prevention. About HIV/AIDS. Atlanta; The
Institute; 2018.
24. WHO (2018). HIV/AIDS Key Facts 2018. Available from:
https://www.who.int/news-room/fact-sheets/detail/hiv-aids - Diakses
Oktober 2018.
25. Kristensen S, Sinkala M, Vermund SH. Transmission of HIV/AIDS Africa.
 Int J STD AIDS. 2002;(1):217–30.
26. Mzingwane ML, Tiemessen CT. Mechanisms of HIV persistence in HIV
reservoirs. Rev Med Virol. 2017;27(2):1–12.
27. S Sleasman JW, Goodenow MM. HIV-1 Infection. J Allergy Clin Immunol.
2003;111:582–92.
28. UNAIDS (2018). JUNP on H. Fact Sheet July 2018 Global Hiv Statistics.
Available from:
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_
en.pdf – Diakses Oktober 2018.
29. Soliman M, Srikrishna G, Balagopal A. Mechanisms of HIV-1 Control.
Curr HIV/AIDS Rep. 2017;14(3):101–9
30. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV.
Nature. 2001;410(6831):980–7.
31. Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher
M, et al. The Qualitative Nature Of The Primary Immune Response To HIV
Infection Is A Prognosticator Of Disease Progression Independent of The
Initial Level Of Plasma Viremia. Proceedings of the National Academy of
Sciences. 1997;94:254–8
32. Center for Disease Control and Prevention. Stages of HIV Infection.
Atlanta; The Institute; 2013.
33. Rastogi S, Agrahari S, Ganga S, Hospital R, Singh UP, Verma A. Clinical
Stages of HIV. Biolixir. 2011;I:29–31.
34. Wood BR, Spach DH. Acute and Recent HIV Infection. CME 2017;10:1–
11.
35. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional
Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang
Dewasa. Jakarta : Kementrian; 2011.

36. Shen L, Farid H, Mcpeek MA. Mental Health Practitioner’s Guide to

HIV/AIDS. Loue S, Biostatistics D of E and, University CWR, Cleveland
O, USA, editors. Evolution. New York: Springer; 2013;I:95–97
37. Page M, Taylor S. Diagnosis,Treatment, and Prevention of STIs and HIV
Antiretroviral. Med (United Kingdom). 2018;46(5):287–92.
38. Yasin NM, Maranty H, Ningsih R. Response to Antiretroviral Therapy
 Undergone by HIV/AIDS Patients. Maj Farm Indones. 2011;22(3):212–22.
39. Karyadi TH. Keberhasilan Pengobatan Antiretroviral (ARV). J Penyakit
Dalam Indones. 2017;4(1):2–4.
40. Nasronudin. HIV dan AIDS : Pendekatan Biologi Molekuler, Klinis, dan
Sosial. Surabaya: Airlangga University Press; 2007. p. 9-10
41. Latif F, Maria IL, Syafar M. Drug Side Effects on Adherence to
Antiretroviral Treatment among People Living with HIV/AIDS. J Kesehat
Masy Nas. 2014;9(2):101–6.
42. Salwa A. Evaluasi Penggunaan Obat Antihipertensi Pada Pasien Hipertensi
Dengan Gagal Ginjal di Instalansi Rawat Inap RSUD Dr. Moewardi Tahun
2010. J Chem Inf Model. 2013;53:1–2.
43. Academy of Manage Care Pharmacy. Drug Utilization Review. Manag
Care Pharm Pract. Washington: The Institute; 2008.
44. Kementerian Kesehatan Republik Indonesia. Modul Penggunaan Obat
Rasional. Jakarta: Kementrian; 2011.
45. Supardi. Populasi Dan Sampel Penelitian. Unisia. 1990;17:100–108.
46. Dahlan MS. Langkah-Langkah Membuat Proposal Penelitian Bidang
Kedokteran dan Kesehatan. Vol. 34. Jakarta: Salemba Medika; 2012.
47. Zetola NM, Pilcher CD. Diagnosis and Management of Acute HIV
Infection. Infect Dis Clin N Am. 2007;21:19–48.
48. Kurnia DA, Solekhah U. Hubungan Pengetahuan HIV/AIDS, Terapi
Antiretroviral, dan Infeksi Oportunistik Terhadap Kepatuhan ODHA dalam
Menjalani Terapi Antiretroviral. J Heal. 2018;5(2):84–7.
49. Prabowo A, Yudasubrata NSY, Tripena A. Hubungan antara Kelompok
Umur, Jenis Kelamin, dan Jenis Pekerjaan pada Penderita HIV/AIDS di
Kabupaten Banyumas. Pros Call f Pa 2017;1779–87.
50. Musthofa SB, Winarti F. The Influencing Factors of a Pre-Marital Sexual
Behavior Among College Students in Pekalongan. J Kesehat Repro
2010;1(1):33-41
51. Yogani I, Karyadi TH, Uyainah A, Koesnoe S. Faktor-faktor yang
Berhubungan dengan Kenaikan CD4 pada Pasien HIV yang Mendapat
Highly Active Antiretroviral Therapy dalam 6 bulan Pertama. J Penyakit Da
 2015;2(4):217–222.
52. Pratiwi NL, Basuki H. Hubungan Karakteristik Remaja Terkait Risiko
Penularan HIV/AIDS dan Perilaku Seks Tidak Aman di Indonesia.
Humaniora 2011;1:346-357
53. Kamila N, Siwiendrayanti A. Persepsi Orang dengan HIV dan AIDS
Terhadap Peran Kelompok Dukungan Sebaya. J Kesehat Masy.
2010;6(1):36–43.
54. Dalimoenthe I. Perempuan dalam Cengkeraman HIV / AIDS : Kajian
Sosiologi Feminis Perempuan Ibu Rumah Tangga. Komunitas.
2011;5(1):41–8.
55. Anwar Y, Barus T, Ginting D. Evaluation of Antiretroviral Adverse Effects
and Managements on HIV/AIDS Patients in Penjaringan District Primary.
Soc Clin Pharm Indones J. 2017;2(1):29–37.
56. Anwar Y, Nugroho SA, Tantri ND. Karakteristik Sosiodemografi, Klinis,
dan Pola Terapi Antiretroviral Pasien HIV/AIDS di RSPI Prof. Dr. Sulianti
Saroso Periode Januari-Juni 2016. Pharm J Indones. 2018;15(01):72–89.
57. Fletcher C, Kakuda T, Anderson P. Weight Loss and Body Mass Index as
Predictors of HIV Disease Progression to AIDS in Adults. J Am Coll Nutr.
2001;20(6):609–15.
58. Yustika K. Evaluasi Penggunaan Antiretroviral Pada Pasien HIV/AIDS Di
RSUD dr. Soehadi Prijonegoro Sragen Periode 2016- 2017. Universitas
Sebelas Maret; 2017.
59. American Society for Microbiology. Pharmacokinetic Interaction between
Rifampin and Zidovudine. 1993;37(7):1426-1430.
60. American Society for Microbiology. Rifampin Reduces Concentrations of
Trimethoprim and Sulfamethoxazole in Serum in Human
Immunodeficiency Virus-Infected Patients. 2001;45(11):3238-3241.
61. Yenny Y, Trisakti U, Agus N. Pharmacokinetic interaction between
efavirenz and rifampicin in healthy volunteers. J Clin Pharmacol Ther.
2011;49:162–168.
62. Syamsudin. Interaksi Obat Konsep Dasar dan Klinis. In Jakarta:
Universitas Indonesia; 2011. p. 1–12.